TriSalus Life Sciences Inc (TLSI) Kazanmak

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company is headquartered in Westminster, Colorado and currently employs 102 full-time employees. The company went IPO on 2020-12-18. The firm is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.